GB1590525A - Biological analysis - Google Patents
Biological analysis Download PDFInfo
- Publication number
- GB1590525A GB1590525A GB5174076A GB5174076A GB1590525A GB 1590525 A GB1590525 A GB 1590525A GB 5174076 A GB5174076 A GB 5174076A GB 5174076 A GB5174076 A GB 5174076A GB 1590525 A GB1590525 A GB 1590525A
- Authority
- GB
- United Kingdom
- Prior art keywords
- particulate
- reagent
- reagents
- particles
- agglutination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Description
(54) BIOLOGICAL ANALYSIS
(71) We, TECHNICON INSTRUMENTS CORPORATION, a corporation organised under the laws of the State of New York, United States of America, of Tarrytown, New
York 10591, United States of America, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:
This invention relates to the analysis of liquids, particularly but not exclusively biological fluids such as serum, for the presence therein of antigens or antibodies, and provides a method of analysis and a pair of particulate reagents for use therein.In this specification, the symbols "Ag", "Ab" and "Ab:Ag" are used, respectively, for antigens (by which term we include haptens and other substances which can be bound by antibodies or similar binding proteins), antibody(ies) (including similar binding proteins) and antibody: antigen complex(es).
It is well known that Ag will react with an appropriate Ab to form Ab:Ag and most immunoassay procedures make use of this reaction. It is further known to coat particulate materials such as polystyrene (generally referred to as latex) with an Ab or Ag, and then to expose the coated particles to a sample solution under test, to see whether and to what extent the particles become agglutinated. Agglutination indicates the presence in the sample of an Ab or Ag capable of reacting with two or more coated latex particles to cause agglutination.
Whilst the technique of observing agglutination of coated particles is in many respects satisfactory, there are problems in assaying small Ag, i.e. Ag whose molecular weight is less than about 4000. Such Ag are very small relative to the particulate materials used, so that discernible agglutination often does not occur or does not occur to any great extent. The technique is, therefore, not wholly reliable for the assay of small Ag.
We have now devised an improved technique for assaying Ab and Ag in a liquid (both to detect their presence and, if desired, to measure the quantity) which is particularly useful for assaying small Ag (or Ab) and can also be used for larger Ag (or Ab). We have further devised a pair of particulate reagents for use in such assays.
In one aspect, the invention provides a method of testing a liquid for the presence therein of a particular Ag or Ab, which comprises forming a mixture of the liquid with two different microscopic or sub-microscopic particulate reagents, which two reagents mutually agglutinate when incubated together, the particular Ag or Ab under assay inhibiting the mutual agglutination of the two reagents; and determining the presence or absence of the said particular Ag or Ab from the extent of agglutination or non-agglutination of the two particulate reagents.
In another aspect, the invention provides a method of quantitatively assaying a particular
Ag or Ab in a liquid, which comprises Xa) forming a mixture of: (i) a sample of the liquid containing the- said particular Ag or Ab under assay, (ii) a first microscopic or sub-microscopic particulate reagent comprising solid particulate support material carrying a first substance, and
(iii) a second microscopic or sub-microscopic particulate reagent comprising solid particulate support material carrying a second substance, the said first substance being capable of binding with the said second substance to cause the first and second reagents to agglutinate together, at least the first substance also being capable of binding with the particular Ag or Ab in the sample to inhibit the binding between said first substance and said second substance
(b) incubating the mixture to allow the said Ag or Ab to bind with said first substance and to allow any of said first substance not bound to the said particular Ag or Ab to bind with said second substance and so cause agglutination of first and second reagents, and
(c) measuring the extent of agglutination or non-agglutinatiori of the said particulate reagents and-thereby determining the amount of said particular Ag or Ab present in the sample.
In a further aspect, the invention provides a pair of reagents for use in the above methods, wherein the first reagent comprises microscopic or sub-microscopic particles having a first immunochemical substance attached thereto; and the second reagent comprises microscopic or sub-microscopic particles having a second immunochemical substance attached thereto; the first and second substances being different but capable of binding together, when the first and second reagents are mixed, to cause agglutination.
In accordance with the method of the invention, two different particulate reagents are used simultaneously (in contrast to prior art procedures in which only one particulate reagent is used). These two reagents (which together form the pair of reagents of the invention) are such that they will agglutinate when mixed together but remain unagglutinated prior to mixing. For example, one particulate reagent may comprise an Ag or
Ag-conjugate and the other an Ab which will bind with the Ag or Ag-conjugate. Upon mixing the two reagents, the Ab will bind with the Ag (or Ag-conjugate) to cause agglutination of the particles. At least one of the particulate reagents is so chosen, however, that it will also bind with the particular Ab or Ag under assay in the liquid.Binding of the particulate reagent with the free Ab or Ag under assay blocks the binding sites on the particulate reagent so that it is no longer able to bind and agglutinate with the other particulate reagent. The extent of agglutination in the mixture is thus reduced (over that amount which would occur in the absence of the particular Ag or Ab from the liquid) by an amount dependent on the amount of the particular Ag or Ab under assay in the liquid. By observing this phenomenon, the presence of the particular Ab or Ag can be confirmed, and by measuring the extent of agglutination or non-agglutination, the amount of the particular
Ab or Ag can be determined.This is usually most conveniently effected by constructing a standard curve from results obtained using known concentrations of particular Ab or Ag under assay, and then using the curve to determine the (previously unknown) amount of Ab or Ag in a sample under test.
The method of the invention can, we believe, be used with any Ag and it does not require specific Ab on the particulate reagent since specificity may be introduced by the Ag-coated particulate reagent. Thus, for example, suppose the Ab coating on one particulate reagent was non-specific so that it could react with three different Ag and it was desired to assay a fluid sample for only one of these Ag (namely Ag'), then by using an Ag'-coated particulate reagent with the Ab-coated reagent, assay of Ag' can be effected. The technique may also be used in the same manner for the detection and measurement of Ab in a sample.
The particulate reagents of the invention are of microscopic or sub-microscopic size, i.e.
they will generally be smaller than 15 microns and most usually of the order of a few microns or sub-micron in size. Latex particles of such sizes are commercially available. It is known to bind Ab or Ag to microscopic particulate material such as latex. This is usually effected by providing a reactive coating on the particle, and then chemically linking or adsorbing the Ab or Ag thereon. It is also possible in certain circumstances to bind the Ab or Ag directly to the particle (with no intervening coating). Since the manner of preparation of the particulate reagents does not form part of the present invention and is well known in the art, no further description thereof will be given.
Among the Ag and Ab which can be bound to particulate materials (such as latex) for the purposes of this invention are, for example: as Ab, immunoglobulin G (IgG) from human, rabbit, goat and sheep serum, as well as their F (abel fragments; rabbit IgM; as Ag, human
IgM, human placental lactogen, human cr-fetoprotein, human lactoferrin, human serum, albumen, human transferrin, human C-reactive protein and Fc fragment of human IgG; bovine IgG and serum albumin; horse ferritin; IgG's of human, mouse, rat and guinea pig, and the purified sub-classes 1, 2, 3 and 4 of human IgG. Also, we have bound thyroxine conjugates of human serum albumin, IgG and transferrin, bovine albumen and fibrinogen, and horse ferritin; also digoxin conjugates of human and bovine albumin and bovine IgG.
Thyroxine may be bound directly to polystyrene latex particles which have reactive carboxyl groups on their surface.
It is preferred that the particle size of each particulate reagent be substantially uniform and, as will be described in more detail hereinafter, that the particle size of the first particulate reagent be different from (preferably at least twice that of) that of the second particulate reagent.
In carrying out the method of the invention to detect the presence of a particular Ag or
Ab, it is merely necessary to establish whether any inhibition of agglutination has occurred.
When there are relatively large quantities of Ag or Ab present in the sample under assay, it is possible to detect inhibition of agglutination by naked eye by observation through a microscope, the mixture being spread on a microscope slide. One particularly preferred test according to the invention is for detecting the presence of progesterone in cows' milk, wherein there is formed a mixture of the milk, a microscopic or sub-microscopic particulate reagent comprising progesterone or a progesterone conjugate, and a microscopic or sub-microscopic particulate reagent comprising an Ab which will bind both with progesterone and progesterone-conjugate. Examination of the mixture with the naked eye will usually reveal any inhibition of agglutination.It is also possible of course, in the tests to establish the presence or absence of inhibition of agglutination, to use one of the procedures to be hereinafter described in connection with quantitative assays.
In quantitative assays according to the invention, it is necessary to measure the extent of agglutination or non-agglutination of the particulate reagents. This may be effected in a variety of ways. For example, the agglutinated particles may be separated from the non-agglutinated particles, and the number of the latter then measured. Separation may be effected, for example, by filtering or centrifuging or by column chromatography. The number of unagglutinated particles may then be measured by, for example, counting or by using an identifying label (such as, for example, a radioactive atom) on the particulate reagent(s).
In general, however, we prefer to avoid a separation step since this is time-consuming and liable to introduce error. Instead, we prefer to make measurements on the reaction mixture to assess the extent of agglutination or non-agglutination. This may be conveniently effected by using selective counting techniques which are themselves known in the art. In this way, it is possible for example to count the number of particles in a given size range (particles of a size outside this range being ignored).
One known apparatus for effecting this is a Technicon Autocounter. In its basic form, this consists of an optical system such that light is passed through a flowcell through which the diluted sample is pumped at right angles to the light beam. At the other end of the optical system is a photocell, and immediately behind the flowcell is a lens with a central black spot, to prevent light directly traversing the flowcell from reaching the photocell.
When a particle is in the light-beam, a proportion of the incident light is scattered in such a way that it by-passes the black spot, and reaches the photocell. This registers an electronic impulse, and by summing these, a count of the particles in the sample may be made.
When using selective counting techniques, it is highly advantageous that the two particulate reagents be of a different size so that they can be distinguished by the counter.
For such purposes, using particles of micron or sub-micron size, a difference in size of a factor of 2 is usually satisfactory. An illustration, merely by way of example, of operation of a method of the invention using selective counting is as follows. To the sample containing the Ag under assay are added the first and second particulate reagents, of sizes respectively
1 and 0.1 microns. The amount of the first reagent added is known and is in excess of that required to bind with all the Ag in the sample. Part of the first reagent binds with the Ag, and is thereby inhibited from binding with the second reagent particles. Those first reagent particles, however, which have not bound with Ag in the sample, bind with the second particulate reagent to agglutinate.The mixture then contains (i) first reagent particles
(unagglutinated) bound to Ag from the sample, (ii) excess second reagent particles
(unagglutinated), and (iii) agglutinated particles. Since there is a difference in size between the unagglutinated first and second reagent particles, the number of unagglutinated first reagent particles (i) can be counted, and from the count (and standard results) the amount of Ag in the sample can be calculated.
Whilst it is highly preferred to proceed in this (or a similar) manner, it is not essential to use differently sized first and second reagents. Furthermore, it is possible to count the total number of particles, or the agglutinated particles in the mixture if desired, although the
reproducibility of results obtained by counting agglutinates is not always very satisfactory.
The method of the invention is particularly advantageous for assaying small Ag and Ab.
In this connection, assays of steroids and drugs are among the most important.
In order that the invention may be more fully understood, the following Examples are given by way of illustration only.
EXAMPLE 1
This Example illustrates the assay of digoxin.
a) Preparation of Ab-coated latex
Latex particles (0.09p diameter, polystyrene, Dow Chemical Co.) as a 10% by weight
suspension as supplied) was diluted 20-fold in dilute glycine-buffered saline (dGBS-20mM glycine, 34mM NaCl, pH9) containing 0.2 mg/ml of the Rivanol-soluble fraction (prepared by the method of Stastny and Horejsi, Clin. Chim. Acta (1961), 6, 782) of sheep anti-digoxin serum, and incubated at room temperature for 30 minutes. 1/lOth volume of 10 mg bovine serum albumin (bSA) per ml. dGBS was then added (to ensure that the latex was completely coated with protein), and after a further 30 minutes incubation, the coated latex was washed twice by centrifugation and resuspended in dGBS.Finally, the coated latex was resuspended as a 0.5% suspension in GBS (0.1M glycine, 0.17M NaCl, pH 9) containing lmg bSA/ml.
b) Preparation of Ag-coated latex
The same procedure was followed as in (a) except that the latex used was of 1.1cm diameter and incubation was performed at an Ag-conjugate concentration of 4Rg/ml, followed by the addition of 1/10 volume of 10mg/ml transferrin. The Ag-conjugate was prepared by the oxidative coupling of digoxin and ethylene glycol followed by reductive coupling of this complex to the protein. 50 mg digoxin dissolved in 2 ml absolute alcohol was incubated for 25 minutes with 2 ml 0.1M NalO4, then 60 1 of ethylene glycol was added for a further 5 minutes incubation.This reaction mixture was then added to a solution of 60 mg human transferrin in 2 ml water, brought to pH 9.5 by addition of 5%
Na2CO3, and incubated for 45 minutes. 30 mg NaBH4 freshly dissolved in 2 ml water was added and incubation was continued for 3 hours. At the end of this time, the pH of the reaction mixture was reduced to 6.5 by addition of 1 M HCOOH to destroy any unreacted
NaBH4, and after a further hour of incubation, 1 M NH40H was added to raise the pH to 8.5, and the preparation was dialysed against running water for 2 days at 40C. (all other operations were at room temperature).
c) Assay
Sera used for the assay of digoxin were first heated with acid to reduce serum interference. 25 Ill of serum was heated to 560C for 10 minutes with 25 Ill of 0.1 N HC1, then made alkaline by the addition of 10 2 M Na2CO3. To these heated sera were added 25 Ill of
Ab-latex (diluted 1:10 with GBS containing 1 mg bSA/ml) and 25 Ill of conjugate-latex (diluted 1: 4 with GBS containing 1 mg human transferrin/ml). They were then incubated in vertically-positioned tubes agitated horizontally on a shaking incubator for 15 minutes at room temperature.At the end of this time, the tube contents were diluted with 5 ml GBS and after a further 20-fold dilution with GBS containing 0.01% "Tween" 20, passed through the flowcell of a Technicon Autocounter at 2 ml/min. ("Tween" is a trade mark).
The relative numbers of unagglutinated (monomer) latex particles in each sample were determined (as also may be the relative numbers of agglutinated particles) by selective optical counting. Table 1 lists the values obtained.
TABLE 1
Inhibition of agglutination by digoxin in serum
Dioxin. concentration in serum Unagglutinated particles
(ng/ml) (as % of maximum)
0 35
0.31 40
0.625 44
1.25 63
2.5 90
5.0 100
This method has also been successfully applied to the determination of dinitrophenol (DNP), using Ag conjugates of the hapten with bSA. In the selective optical counting of particles, the amount of light scattered by a particle is dependent on the size of the particle; in turn, the electronic impulse generated in the photocell will be proportional to the size of the particle, and particles of different sizes may be counted separately.Table 2 illustrates the improvement in precision of determination (by providing a more extended range for the standard curve) that may be obtained by counting only unagglutinated particles (monomers) as opposed to counting all particles (total). (The results in Table 2 relate to assays of human placental lactogen (HPL)). The Table also illustrates the great increase in sensitivity that may be realized by calculating the ratio of unagglutinated to agglutinated particles (monomer/polymer ratio). By counting particles at all, an increase in sensitivity and precision may be realized by comparison with other methods of end-point determination. Table 3 shows a comparison of the results obtained by particle counting (monomers only) and turbidimetry (optical density at 400 nm) for a set of samples representing a standard curve for digoxin.
TABLE 2
Comparison of counting methods for latex immunoassay of HPL
ngs HPL/ml Total particles Monomers Monomer/polymer ratio
0 100 100 100
2.5 100 100 81
5 100 98 68
10 97 94 55
20 90 82 30
40 78 62 13
60 67 46 8
80 57 36 6
100 50 30 5
160 40 22 5
Each value is expressed as a percentage of that obtained in the absence of HPL.
TABLE 3
Comparison of counting vs. turbidimetry for latex immunoassay of digoxin
Digoxin concentration in serum Particle count
(ng/ml) (monomers) Turbidity
0 35 68
0.31 40 74
0.625 44 71
1.25 63 82
2.5 90 100
5.0 100 100
Each value is expressed as a percentage of that found in the presence of 5ng digoxin/ml (maximal inhibition).
EXAMPLE 2
This Example illustrates the assay of thyroxine.
a) Preparation of thyroxine-coupled latex
Latex particles (0.857 ij diameter, carboxylate-modified polystyrene, Dow Chemical Co.) as a 10% weight suspension (as supplied) was diluted 20-fold in phosphate buffered saline (PBS : 50 mM in sodium phosphate, 0.17 M in NaCl, pH 6), centrifuged (at 12,000 x g at 40 for 10 minutes), and resuspended in fresh PBS to a final weight suspension - of 2%. A solution of 25 ug thyroxine and 50 ug 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride in 1 ml PBS was prepared at 0 , and 250 'Ll of the washed latex suspensions added.After incubation at 0 for 1 hour,-250 itl of 25% ethanolarnine in PBS was added, and the incubation prolonged for 30 minutes. The latex was then washed twice by centrifugation and resuspension in fresh PBS (1 ml each time), and then dialysed for 16 hours at 4" against 1 1 PBS. It was finally centrifuged and resuspended in 1 ml glycine-buffered saline containing 1% bovine albumin rbSA).
b) Assay of thyroxine by mixed agglutination
(i) Preparation of Ab-coated latex
The method of this latex preparation was exactly the same as for the assay of digoxin (Example 1) except that the Ab was from rabbit anti-thyroxine (T4) serum.
(ii) Preparation of Ag-coated latex
As above under (a).
(iii) Assay
Sera to be assayed for T4 are first mixed with an equal volume of 1 mM 1-anilino-napthalene-8-sulphonic acid in 75 mM sodium diethyl-barbiturate, pH 9.2. 50 Ill of this diluted serum is then incubated with 25 Ill 0.01% suspension of Ab-latex in GBS containing 1% bSA, and 25 1 0.1% suspension of Ag-latex in the same buffer in the same
way as for the assay of digoxin (Example 1). Table 4 illustrates typical results obtained using
this system.
TABLE 4
ng T4/ml serum Particle concentration (% maximum)
0 48
10 51.5
50 59.5
200 89
The maximum value in this case was for the Ag-latex alone, all the above values being
found in the presence of Ag-latex as well.
EXAMPLE 3
Example 1 was repeated using latex particles of the same (as opposed to different) size
and the following results were obtained:
TABLE 5
Inhibition of agglutination by digoxin in serum
Unagglutinated Particles
(as % of maximum)
Digoxin concentration Equal-sized Different-sized
in serum (ng/ml) latex latex
0 60 21
1 78 30
4 95 76
10 100 100
Claims (27)
1. A method of testing a liquid for the presence therein of a particular Ag or Ab, which comprises forming a mixture of the liquid with two different microscopic or sub-microscopic particulate reagents, which two reagents mutually agglutinate when incubated together, the particular Ag or Ab under assay inhibiting the mutual agglutination of the two reagents; and determining the presence or absence of the said particular Ag or Ab from the extent of agglutination or non-agglutination of the two particulate reagents.
2. A method according to claim 1 wherein the two different particulate reagents each comprise latex particles carrying a reagent.
3. A method according to claim 1 or 2 wherein one particulate reagent comprises an Ag or Ag-conjugate, and the other particulate reagent comprises an Ab which will bind with the said Ag or Ag-conjugate, and wherein either the Ab or the Ag or Ag-conjugate is one which will bind with the particular Ag or Ab under assay to inhibit agglutination of the two particulate reagents.
4. A method according to claim 1, 2 or 3 wherein the mixture is spread on a microscope slide and the extent of agglutination or non-agglutination is determined by naked-eye observation or through a microscope.
5. A method according to any of claims 1 to 4 for detecting the presence of progesterone in cows' milk, wherein there is formed a mixture of the milk, a microscopic or sub-microscopic particulate reagent comprising progesterone or a progesterone conjugate, and a microscopic or sub-microscopic particulate reagent comprising an Ab which will bind both with progesterone and progesterone-conjugate.
6. A method of quantitatively assaying a particular Ag or Ab in a liquid, which com srises (a) forming a mixture of:
(i) a sample of the liquid containing the particular Ag or Ab under assay,
(ii) a first microscopic or sub-microscopic particulate reagent comprising solid particulate support material carrying a first substance, and
(iii) a second microscopic or sub-microscopic particulate reagent comprising solid particulate support material carrying a second substance, the said first substance being capable of binding with the said second substance to cause the first and second reagents to agglutinate together, at least the first substance also being capable of binding with the particular Ag or Ab in the sample to inhibit the binding between said first substance and said second substance
(b) incubating the mixture to allow the said Ag or Ab to bind with said first substance and to allow any of said first substance not bound to the said particular Ag or Ab to bind with said second substance and so cause agglutination of first and second reagents, and
(c) measuring the extent of agglutination or non-agglutination of the said particulate reagents and thereby determining the amount of said particular Ag or Ab present in the sample.
7. A method according to claim 6 for the assay of a particular Ag, wherein the first substance is an Ab capable of binding with the Ag under assay or with a conjugate thereof, and the second substance is the same Ag as is under assay or a conjugate thereof.
8. A method according to claim 6 for the assay of a particular Ab, wherein the first substance is an Ag or Ag-conjugate which is capable of binding with the said Ab, and the second substance is an Ab which is capable of binding with the said Ag or Ag-conjugate.
9. A method according to claim 6, 7 or 8 wherein the particle size of each particulate reagent is substantially uniform.
10. A method according to claim 9 wherein the particle size of the first particulate reagent is different from that of the second particulate reagent.
11. A method according to claim 10 wherein the particle size of the first particulate reagent is at least twice that of the second particulate reagent.
12. A method according to any of claims 6 to 11 wherein, in step (c), the extent of agglutination or non-agglutination is determined by counting agglutinated and/or nonagglutinated particles.
13. A method according to claim 12 wherein the said counting of the particles is effected whilst they are present in the mixture.
14. A method according to claim 13 wherein non-agglutinated particles are selectively counted by optical techniques.
15. A method according to claims 11 and 14 wherein non-agglutinated first particulate reagent in the mixture is selectively counted, and wherein in step (a) a known amount of first particulate reagent is included in the mixture.
16. A method according to any of claims 6 to 12 wherein, in step (c),the agglutinated particles are separated from the non-agglutinated particles.
17. A method according to claim 16 wherein either the first particulate reagent or the second particulate reagent comprises an identifying label, and the extent of agglutination or non-agglutination is measured by assay of the label in the separated particles.
18. A method according to any of claims 6 to 17 wherein one or both said particulate reagents comprise latex.
19. A method according to any of claims 1 to 4 or 6 to 18 wherein the Ag or Ab under assay has a molecular weight of less than 4000.
20. A method according to claim 19 wherein the Ag under assay is a steroid or a drug.
21. A method according to any of claims 1 to 4 or 6 to 20 which is carried out on an automated continuous flow basis.
22. A method according to claim 1 substantially as herein described in Example 1, 2 or 3.
23. A pair of reagents for use in the method of claim 1, wherein the first reagent comprises microscopic or sub-microscopic particles having a first immunochemical substance attached thereto; and the second reagent comprises microscopic or submicroscopic particles having a second immunochemical substance attached thereto; the first and second substances being different but capable of binding together, when the first and second reagents are mixed, to cause agglutination.
24. Reagents according to claim 23 wherein the first reagent particles are of a different size from the second reagent particles.
25. Reagents according to claim 24 wherein the first reagent particles are at least twice the size of the second reagent particles.
26. Reagents according to claim 23, 24 or 25, wherein both reagent particles comprise latex and wherein the first and second substances are selected from antigens and antibodies.
27. Reagents according to claim 23, 24, 25 or 26 wherein each reagent is of substantially uniform particle size.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB5174076A GB1590525A (en) | 1976-12-10 | 1976-12-10 | Biological analysis |
DE19772754645 DE2754645C2 (en) | 1976-12-10 | 1977-12-08 | Method for the detection and determination of antigens or antibodies in liquids |
CA292,691A CA1089360A (en) | 1976-12-10 | 1977-12-08 | Antigen or antibody testing using inhibition of the agglutination of two particulate reagents |
FR7737122A FR2392387A1 (en) | 1976-12-10 | 1977-12-09 | METHOD FOR DEMONSTRATING AN ANTIGEN OR A PARTICULAR ANTIBODY IN A LIQUID |
JP14777277A JPS53104726A (en) | 1976-12-10 | 1977-12-10 | Test method of liquid containing specific antigen ag or antibody ab |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB5174076A GB1590525A (en) | 1976-12-10 | 1976-12-10 | Biological analysis |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1590525A true GB1590525A (en) | 1981-06-03 |
Family
ID=10461194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB5174076A Expired GB1590525A (en) | 1976-12-10 | 1976-12-10 | Biological analysis |
Country Status (5)
Country | Link |
---|---|
JP (1) | JPS53104726A (en) |
CA (1) | CA1089360A (en) |
DE (1) | DE2754645C2 (en) |
FR (1) | FR2392387A1 (en) |
GB (1) | GB1590525A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0090966A1 (en) * | 1982-04-05 | 1983-10-12 | American Hospital Supply Corporation | Process for antigen determination |
WO1989001161A1 (en) * | 1987-07-28 | 1989-02-09 | International Institute Of Cellular & Molecular Pa | Turbidimetric assay |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4191739A (en) * | 1977-10-17 | 1980-03-04 | General Electric Company | Antigen-antibody reaction assay employing particle aggregation and resistive pulse analysis |
GB2045431B (en) * | 1979-02-26 | 1983-04-20 | Technicon Instr | Immunoassay utilising two particulate reagents |
DE2918342A1 (en) * | 1979-05-07 | 1980-11-20 | Behringwerke Ag | LATEX REAGENT |
JPS5821166A (en) * | 1981-07-30 | 1983-02-07 | Fujitsu Ltd | Separation of material to be measured |
GB2123146B (en) * | 1982-06-28 | 1985-09-25 | Abbott Lab | Dual parameter flow immunoassays |
JPH0619349B2 (en) * | 1983-11-22 | 1994-03-16 | 東亜医用電子株式会社 | Body fluid component analysis method and apparatus |
JPH0619350B2 (en) * | 1984-05-17 | 1994-03-16 | 東亜医用電子株式会社 | Body fluid component analysis method and apparatus |
JPS61120060A (en) * | 1984-11-16 | 1986-06-07 | Dai Ichi Pure Chem Co Ltd | Fully automatic and continuous analysis instrument |
JPH056646Y2 (en) * | 1987-02-24 | 1993-02-19 | ||
CN111965277A (en) * | 2020-08-06 | 2020-11-20 | 天津科德通生物科技有限公司 | Automatic collection device for antibody purification effluent liquid |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3639558A (en) * | 1968-02-19 | 1972-02-01 | Louis Csizmas | Immunological reagent particles having proteinaceous materials covalently bonded thereto |
-
1976
- 1976-12-10 GB GB5174076A patent/GB1590525A/en not_active Expired
-
1977
- 1977-12-08 CA CA292,691A patent/CA1089360A/en not_active Expired
- 1977-12-08 DE DE19772754645 patent/DE2754645C2/en not_active Expired
- 1977-12-09 FR FR7737122A patent/FR2392387A1/en active Granted
- 1977-12-10 JP JP14777277A patent/JPS53104726A/en active Granted
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0090966A1 (en) * | 1982-04-05 | 1983-10-12 | American Hospital Supply Corporation | Process for antigen determination |
WO1989001161A1 (en) * | 1987-07-28 | 1989-02-09 | International Institute Of Cellular & Molecular Pa | Turbidimetric assay |
Also Published As
Publication number | Publication date |
---|---|
DE2754645C2 (en) | 1986-11-20 |
DE2754645A1 (en) | 1978-06-22 |
CA1089360A (en) | 1980-11-11 |
JPS6217188B2 (en) | 1987-04-16 |
JPS53104726A (en) | 1978-09-12 |
FR2392387B1 (en) | 1982-05-14 |
FR2392387A1 (en) | 1978-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4184849A (en) | Mixed agglutination | |
US4279617A (en) | Iummunoassay involving agglutination | |
CA1332043C (en) | Latex agglutination immunoassay in the presence of hemoglobin | |
EP0267317B1 (en) | Method for the detection of proteins and viruses | |
US5518887A (en) | Immunoassays empolying generic anti-hapten antibodies and materials for use therein | |
EP0321261B1 (en) | Use of immobilized biotinylated receptor in test device, kit and method for determining a ligand | |
JPH03502246A (en) | Coagulation methods for the analysis of substances | |
EP0124352A2 (en) | Protected binding assay | |
CA1174596A (en) | Particle agglutination assay | |
EP0564494B1 (en) | Test method and reagent kit therefor | |
WO1993020446A1 (en) | Immunoassays employing generic anti-hapten antibodies and materials for use therein | |
GB1590525A (en) | Biological analysis | |
US4828978A (en) | Agglutination reagent and method of preparing same | |
JP3220546B2 (en) | Method for measuring antigen or antibody in the presence of immune complex | |
EP0565949A2 (en) | Method for the quantitative determination of a free form of substances present in biological fluids | |
CA1234044A (en) | Specific binding assay reagent | |
US5843794A (en) | Technique for the prevention of false positive reactions in immunological testing due to C1 and C1q components of the complement and method for screening for rheumatic factor | |
EP0280561B1 (en) | Agglutination reagent and method of preparing same | |
EP0260079A1 (en) | Method of assay | |
AU732232B2 (en) | Method of coupling ligands to a solid phase in acidic solution and anionic surfactant | |
EP0586693A1 (en) | Technique for prevention of false reactions in immunological testing | |
JPH03267759A (en) | Immunological measurement method using immobilized red cells | |
JPH02231566A (en) | Enzyme labeled receptor composition, diagnosis kit and utilization thereof for ligand measurement | |
JPH1130616A (en) | High sensitive immunological measuring method and measuring kit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PS | Patent sealed | ||
732 | Registration of transactions, instruments or events in the register (sect. 32/1977) | ||
PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19941117 |